VE Ablation in Bileaflet Mitral Valve Prolapse
VAs related to BiMVPS as previously reported. 9 In all patients, VA was refractory to medical therapy. Complex VE was defined as the presence of VE couplets, ventricular bigeminy, nonsustained VT, or sustained VT. We defined symptomatic VA if it was associated with patient-reported poor quality of life, syncope, out-of-hospital cardiac arrest, or need for recurrent implantable cardioverter defibrillator (ICD) shocks. Patients were excluded if there was coexistent (1) severe MR 21 ; (2) cardiac channelopathy, Wolff-Parkinson-White syndrome, ischemic or nonischemic cardiomyopathy, coronary artery disease, congenital coronary artery anomalies, and known connective tissue disease; (3) positive family history of channelopathy, cardiomyopathy, unexplained sudden death, or out-of-hospital cardiac arrest; or (4) aged >60 years at the time of index ablation procedure. Internal review board approval was obtained to prospectively collect data on consenting patients undergoing catheter ablation. Additional internal review board approval was obtained for a retrospective analysis of ablation and clinical details of patients with MVP undergoing ablation.
Electrophysiological Study and Radiofrequency Ablation
Before electrophysiological study and ablation, all patients routinely underwent echocardiographic evaluation and additional cardiac imaging as deemed necessary by the referring clinician. Cardiac magnetic resonance imaging was performed using a 1.5-T magnetic resonance imaging scanner (Signa Twin Speed Excite; General Electric, Waukesha, WI), with precautions to limit the specific absorption rate to <1.5 W/kg in patients with previous cardiac devices and acquisition of delayed-enhancement images for detection of late gadolinium enhancement, using methods previously detailed. 22, 23 Preablation 12lead Holter tracings and ICD electrograms were reviewed to characterize the clinically dominant or VF-triggering VE with the intention to ablate such triggers. Antiarrhythmic drugs were discontinued at least 5 half-lives before the procedure.
The electrophysiological study was performed as per standard protocol. 16 Light or conscious sedation with short-acting anesthetic agents was used during initial sheath placement and was stopped before arrhythmia induction and mapping. All patients received intravenous heparin during the procedure. Standard multielectrode intracardiac catheters were positioned under fluoroscopic guidance in the right atrium, His bundle region, coronary sinus, and right ventricle. The LV was accessed either via a transseptal or retrograde aortic approach. Surface ECGs and intracardiac electrograms were continuously monitored and recorded by an electrophysiological laboratory system (Prucka Engineering, Milwaukee, WI). The Carto system (Biosense Webster, New Brunswick, NJ) was used to construct detailed (>100 distinct endocardial mapping points) 3-dimensional electroanatomic maps, supplemented by intracardiac echocardiography for localization of intracavitary structures, with adjunctive activation maps of the clinical VA and endocardial substrate (bipolar and unipolar voltage) maps of the ventricles. Mapping and ablation was performed with a standard 3.5-or 4.0-mm tip catheter (NaviStar ThermoCool; Biosense Webster) with or without irrigation. Radiofrequency was delivered in unipolar fashion from the catheter tip with temperature and impedance monitoring.
Intracardiac Echocardiography
Intracardiac echocardiography was performed from the right atrium or right ventricle using an 8-or 10-F linear phased-array catheter (Siemens Corporation, Erlangen, Germany) to define cardiac anatomy, document catheter location, and tissue contact, especially in relation to endocavitary structures, such as the PMs, and to monitor for procedural complications. The images were optimized by varying the frequency (5.5-8.5 MHz), depth, gain, and transmit focus. 16
Definition of Arrhythmia Mechanism and Choice of Ablation Site
Standard programmed stimulation was performed for arrhythmia induction with isoproterenol infusion (2-20 μg/min) as necessary. Induced VAs were compared with stored surface ECG tracings and ICD electrograms to determine clinical relevance. 24 Reentrant arrhythmias were identified in the presence of mapping of >70% of the VT cycle length or coupling interval or according to entrainment criteria for critical portions of the VT circuit. Intracardiac electrograms were presumed to originate from the fascicular/Purkinje tissue 12 when they were characteristically sharp (with a rapid upstroke velocity), high frequency, of a short duration, and preceded the earliest intracardiac ventricular electrogram by an isoelectric interval during VE but not during sinus or atrial paced rhythm ( Figure 1 ). Ablation targeted sites with early Purkinje potentials during VE, 11, 13 particularly with similar Purkinje to local ventricular electrogram time during VE as pacing stimulus to local ventricular electrogram time at sites of high correlation pacemaps (matching in all leads of standard 12lead surface electrograms), as well as adjacent Purkinje potentials given limitations in precisely targeting a particular Purkinje fiber or fibers of VE origin. When deemed necessary, additional ablation to eliminate any abnormal electrograms adjacent to the target sites was performed. Abnormal electrograms were defined as fractionated (prolonged, multicomponent, and low amplitude), split (having discrete widely separated deflections), or delayed (myocardial: extending after the end of the surface QRS complex; Purkinje: onset after the start of surface ECG or local ventricular electrogram in sinus or atrial paced rhythm) as previously reported. 25, 26 Pacemapping was reserved to identify non-Purkinje myocardial targets, such as in the ventricular outflow tracts, when activation mapping was limited by infrequent or nonsustained arrhythmia during the study. Noninducibility of clinical arrhythmia and reduction in clinical VE burden were the end points for ablation.
Postablation Care and Follow-Up
Follow-up evaluation was performed in all patients 4 to 12 weeks post ablation and scheduled thereafter at 6-to 12-month intervals. ECGs, Holter monitors, and echocardiograms were routinely obtained, and ICD interrogation was performed, where appropriate.
Statistical Analysis
Given the small sample size, all observations were viewed as hypothesis generating, and no formal statistical comparisons were performed.
WHAT IS KNOWN
• Bileaflet mitral valve prolapse may be associated with malignant ventricular arrhythmia in some patients.
WHAT THE STUDY ADDS
• Bileaflet mitral valve prolapse syndrome is characterized by fascicular and papillary muscle ventricular ectopic impulses that may trigger ventricular fibrillation. • The Purkinje system seems to play a central role in arrhythmogenesis in bileaflet mitral valve prolapse.
• Catheter ablation can be useful in reducing the burden of symptomatic arrhythmias and implantable cardioverter defibrillator shocks, but recurrence is common.
Results

Patient Demographics
Fourteen patients (13 women; age at index ablation, 33.8 [21.0-58.7] years) with bileaflet MVP meeting study criteria underwent 20 ablation procedures between February 2007 and March 2015 at our institution. Six patients had sustained previous cardiac arrests and recurrent ICD shocks for drugrefractory VE-triggered VF, and 8 patients had symptomatic drug-refractory VE without a previous cardiac arrest. The 8 patients without ICD had no previous history of syncope or cardiac arrest.
The 2 groups had similar baseline demographics, degree of MR, LV ejection fraction, ECG findings, VE burden, number of different VE morphologies on Holter monitoring, VE couplets with alternating axis, and polymorphic nonsustained VT ( Table 1 ). Manual caliper measurements on all available ECG tracings demonstrated that the shortest VE coupling interval in patients with cardiac arrest was longer than in nonarrest patients before ablation (403±59 versus 329±25 ms), with no difference in maximum variation in coupling interval for a given VE or the shortest inter-VE interval for VE couplets ( Table 1 ). The LV ejection fraction was preserved in all but one patient (who had a previous cardiac arrest) in whom the borderline low ejection fraction (45%) was deemed secondary to the high burden of VE and not a primary myopathic process. Cardiac magnetic resonance imaging was performed before index ablation in 5 patients (2 with previous cardiac arrest; of whom, 1 had an ICD at the time of imaging) and demonstrated no areas of delayed gadolinium enhancement. In a sixth patient, without previous cardiac arrest, imaging 
Index Electrophysiological Study and Ablation
Arrhythmia Induction VE was either spontaneous or induced with low-dose isoproterenol infusion (4 studies), atrial and ventricular burst pacing (1 study), or ventricular burst pacing with isoproterenol (3 studies). Five of 14 (36%) patients developed sustained VA during the electrophysiological study. Three of these patients had monomorphic VT further characterized as fascicular reentry ( Figure 2 ). The other 2 patients (both with previous cardiac arrest) had right ventricular pacing-induced VF during isoproterenol infusion requiring defibrillation ( Figure 3 ). A sixth patient (with previous cardiac arrest) had a VE focus that seemed to arise from an area of mechanical trauma from a redundant mitral valve cord; burst pacing at this site induced clinical VE and VF (Movies in the Data Supplement).
Electrogram Findings
Bipolar and unipolar voltage maps were normal in all patients. Abnormal LV fascicular potentials were evident in all 6 patients with previous cardiac arrest and all cases of sustained VA during the electrophysiological study. Abnormal LV fascicular signals were defined as fractionated, delayed, or middiastolic Purkinje electrograms. Two patients with previous cardiac arrest also had markedly abnormal regions of slowed conduction and mid-diastolic activation in the myocardium surrounding the PM (Figure 2 ). Tables 2 and 3 ). In one of these patients, the left posterior fascicular VE was not targeted for ablation given the VT clinically seen and also targeted was identified in the region of the right ventricular outflow tract. Other foci were the outflow tracts in 4 of 14 (29%; 2 right and 2 left), mitral annulus in 2 of 14 (14%), and in 1 patient successful ablation was in the coronary venous system over the basal anterolateral LV, suggesting epicardial origin.
Sites of Successful Ablation (PMs, Fascicles, Outflow Tracts, and Mitral Annulus)
Coupled VE from discrete sites were noted in 2 patients during the index procedure and in a third patient during the repeat procedure. In one, the alternating foci were mapped to underneath (ventricular to) the left coronary cusp, inferoseptal region of the mitral annulus, and posterior PM. In the second patient, alternating foci were mapped to a deep LV septal focus and anterior PM. In another patient, alternating foci were noted at a repeat procedure 131 days after index ablation and mapped to the anterior PM and posterior fascicle (exiting onto the posterior PM).
Ablation-induced VF occurred in 4 of 6 patients with previous cardiac arrest and 2 of 8 nonarrest patients; 4 of 14 (29%; 3 with previous cardiac arrest) during index ablation and 3 of 6 (50%; 2 with previous cardiac arrest) during repeat ablation (Tables 2 and 3; Figure 3 ). At each instance, ablation was temporarily stopped to allow for defibrillation, with reinitiation of ablation on termination of VF, such that ablation was continued to completion in all instances. In the 4 patients with previous cardiac arrest, ablation was targeting a clinical VE of Purkinje origin (1 anterior and 1 posterior PM; 1 anterior and 1 posterior fascicular system). In the 2 nonarrest patients, a focus at the anterior PM was being targeted, which in one was felt to be from conduction tissue as Purkinje electrograms were evident at the site of successful ablation. at index ablation, with no difference between patients with and without previous cardiac arrest (4/6 versus 5/8, respectively). In 7 of 9 (78%) of these, the targeted PM VE was fascicular in 
Purkinje Origin Arrhythmia
A dominant clinical VE/VT focus of Purkinje origin was identified in 11 of 14 (79%), more often in patients with cardiac arrest (6/6 versus 5/8 nonarrest). The Purkinje focus was located at the PM in 2 of 11, the LV fascicular system in 4 of 11, or both in 5 of 11 ( Figure 4 ). The involved fascicular system was usually either adjacent or proximal to the PMs, with the VE occasionally exiting onto a PM. Purkinje potential to QRS duration in VE at the site of successful ablation was median 42 (30-80) ms. Ablation of a Purkinje focus was consolidated with additional lesions delivered to diseased LV fascicular tissue in 5 patients (all with previous cardiac arrest; in 2 patients, this was during the second ablation procedure). In patients with versus without Purkinje targets, there was no difference in preablation QRS duration (95±11 versus 88±7 ms), QTc (459±29 ms versus 464±3 ms), or HV interval (50±8 versus 45±7 ms 
Immediate Procedural Outcomes
Acute procedural success (noninducibility or reduction in clinical VE burden) at index ablation was seen in 12 of 14 (86%). QRS duration or His-ventricular (HV) interval did not change after ablation ( Table I in the Data Supplement) . There were no complications at the end of the procedure. The 2 procedures that were not acutely successful were terminated early because of concern of causing mitral valve dysfunction in one and in the other occurrence of a clinically different VE beat compared with those targeted at the end of the procedure which triggered recurrent VF post procedure and was medically managed.
Repeat Electrophysiological Study and Ablation
A repeat ventricular ablation procedure was performed in 6 of 14 (36%) patients (3 with previous cardiac arrest; 3 nonarrest) at median 302 (131-1574) days from index ablation ( Table 3) . A new LV focus was evident in 5 of the 6 patients at repeat ablation performed 288 to 1574 days from index ablation, whereas 1 patient with limited ablation of a papillary focus at index procedure required reablation 131 days later. Three of the previous cardiac arrest patients undergoing repeat ablation for recurrent VE-induced VT/VF had either non-PM fascicular foci (2/3) or PM Purkinje foci (1/3) in the LV at 288 days, 312 days, and 4 years after index procedure. The indication for repeat ablation in the 3 nonarrest patients were high-grade VE refractory to medical therapy, with successful ablation of either LV PM or fascicular foci in all 3 patients. All 6 patients had acute procedural success with no complications.
Follow-Up
All but 2 patients were followed up in person at Mayo Clinic; the remaining 2 patients were followed up through local physicians, with telephonic and written communication with the patient documented in the electronic medical record at our institution. After a median of 768 (39- . A change in mitral function after ablation was noted in 1 patient, whose MR increased from mild to moderate after a second ablation procedure. Two patients (1 cardiac arrest with moderate MR; 1 nonarrest) with mild MR underwent mitral repair because of recurrent highburden VE 1.2 and 3.8 years after a second ablation procedure, respectively, both with improvement in symptoms, and documented VE burden reduction from 16% to 2.5% in the nonarrest patient. One patient required cervical sympathectomy because of recurrent VE-triggered VF while on nadolol and flecainide. There was one death 521 days post ablation secondary to elective extraction of a malfunctioning ICD lead.
Discussion
The main findings of this study are that ablation is feasible in patients with symptomatic, drug-refractory VE in the setting of BiMVPS; fascicular and PM VEs often trigger VF in these patients, but VE may also involve the outflow tract and mitral annulus; ablation can reduce symptomatic VE and appropriate ICD shocks during follow-up; and late recurrence can arise from sites not targeted at the initial ablation.
In the subgroup of patients with previous cardiac arrest, targeting the VE triggers resulted in a reduction in appropriate ICD shocks but did not affect overall VE frequency. In the subgroup without previous cardiac arrest, targeting the most frequent ectopics resulted in a reduction in VE burden. In both groups, there was a reported reduction in symptoms from VE. Our observation that in 5 of 6 patients, recurrent VE was mapped and ablated at distinct foci from those identified at index ablation suggests that the clinical course is progressive in some and patients, therefore, need to be followed up carefully for arrhythmia recurrence.
There seems to be potential for proarrhythmia during or immediately after ablation. We reported 1 patient who developed VF storm acutely after ablation and, several others developed intraprocedural VF. This transient increased risk of malignant VA was observed when ablating either a Purkinje target or PM, which frequently have Purkinje signals at sites of origin of VA. 27 The marked proarrhythmic effect of radiofrequency ablation of Purkinje tissue has been observed before, 13 including when Purkinje triggers exist at PMs. 18, 19 Our current study adds to the understanding of the potential characteristics of proarrhythmia in these patients. Previous studies, including Barlow original description in 1968, have reported on the association of myxomatous MVP with sudden death in the absence of severe MR. [1] [2] [3] [4] [5] [6] 10 Others have demonstrated the association of VA with mitral dysjunction 28 and longer mitral valve leaflets. 29 The current study compared electrophysiological study findings in patients with and without previous cardiac arrest. Patients with previous cardiac arrest were differentiated by the universal identification of VE arising from Purkinje tissue as clinical VF triggers with the presence of fractionated, split, and delayed Purkinje potentials in these patients, suggesting diseased Purkinje tissue. Fascicular tissue disease was also present in those who did not have a history of syncope or cardiac arrest but in whom standard ventricular pacing maneuvers induced sustained VA. Although none of the patients in this study had delayed enhancement on magnetic resonance imaging before ablation, previous studies of patients with MVP have demonstrated that delayed enhancement consistent with myocardial fibrosis in the region of the mitral subvalvular apparatus is both common and associated with VA. 10, 30 The cause for these tissue abnormalities in BiMVPS is currently unknown. It is unlikely that these patients have a coincident, unrelated idiopathic VF with Purkinje triggers amenable to ablation 12, 13, 19 because consistent localization of VE foci and abnormal tissue with slow conduction to the vicinity of the subvalvular mitral apparatus suggests a structural association. What remains to be fully defined, however, is whether the valvular abnormality is causative, through mechanical trauma from the interaction of mitral leaflet and chordal redundancy with the ventricular cavity, or if there is an associated conduction tissue abnormality 31 or another structural predisposition, such as mitral disjunction. 3, 32 A causative association is supported by the observed spatiotemporal association of a culprit focus with chordal trauma to a fascicular site in 1 patient and symptomatic improvement and VE burden reduction after mitral repair in 2 others without severe MR. VE foci were also found at the mitral annulus (2/14; 14%) and outflow tracts (4/14; 29%). Previous studies have demonstrated structural abnormalities at the mitral annulus in patients with bileaflet MVP 3, 28 although the outflow tract ectopy may have an associated structural cause or represent a coincident abnormality (second hit) on account of high background population prevalence although these explanations are hypothetical as no histological data were available. Published data on VA reduction after mitral valve surgery in patients with mitral prolapse is *One nonarrest patient had successful ablation in the coronary venous system, suggesting an epicardial origin from basal anterolateral LV, and another had successful ablation of a deep septal (possibly fascicular) focus from the LV endocardium.
†1 patient had VF storm immediately post ablation. ‡One patient with ongoing polymorphic ectopy with isoprenaline from anterior papillary muscle which was not ablated because of concern of causing mitral valve dysfunction.
§Both patients also had a papillary exit site from a proximal fascicular focus. [33] [34] [35] [36] [37] [38] [39] with some investigators reporting no benefit. 6 Both localized reentry and triggered automaticity have been implicated as the mechanism of VE in MVP, with triggering from either a remote VE focus or a sinus beat. 40, 41 The mechanism responsible for most of the patients' VE was not fully characterized, including the observed coupling of ectopics from remote sites in this study and previously 9 although these were successfully mapped and ablated as focal origin arrhythmias. We did not elucidate the mechanism underlying the observation that the shortest VE coupling interval was longer in the group with malignant VA and with Purkinje origin VA (403±59 versus 329±25 ms). Both short-coupled (245±28, 42 302±52, 43 297±41 ms 44 ) and long-coupled (409±62 ms 45 ) VEs have been previously reported with idiopathic VE-induced VF, and whether this group is a spectrum of these populations or a separate entity in view of electrogram evidence of localized fascicular or myocardial disease is unknown. Previous studies have reported an association between increased variability in VE coupling intervals and risk of malignant VA, with similar coupling interval variability 46, 47 to our population, although no differences were seen between the groups with and without previous cardiac arrest. One possible mechanism of this variability is electrotonic modulation by surrounding myocardium of a protected parasystolic focus, 48, 49 such as a Purkinje fiber, which was the tissue target tissue in 11 of the 14 patients.
Study Limitations
This study was limited by its retrospective design, intermediate term follow-up, and differences in ascertainment bias between the 2 subgroups. Because of the small sample size, formal statistical comparisons between groups were not possible, and all observed numeric group differences should be viewed only as hypothesis generating. Although the indication for ICD implantation in cardiac arrest survivors is clear, predicting who with BiMVPS would benefit from ICD implantation in the absence of previous cardiac arrest remains challenging. Whether ablation-modified subsequent risk of VF in any of the nonarrest patients is unknown although none has had syncope, cardiac arrest, or ICD placement on follow-up. The prevalence of this phenotype among patients with MVP in general is currently unknown. The study was able to identify sites of origin associated with sudden cardiac death in MVP, with implications for underlying mechanisms. However, it should not be used to draw conclusions on the prevalence of the various proarrhythmic manifestations of the condition, which includes isolated VE, monomorphic VT, and triggered VF. This study was undertaken to identify arrhythmic mechanisms in the original MVP cohort described by our group, 9 in which all patients had myxomatous bileaflet MVP. There may be other forms of MVP, which predispose to VA and sudden death. 40 In addition, all patients with severe mitral valve dysfunction or significant ventricular dysfunction were excluded, and these factors may further alter the electrophysiological substrate associated with the condition. About the patient with mild LV dysfunction, our conclusion was that this did not represent a separate disease process to the others in this series, as MR was mild, workup for other etiologies of cardiomyopathy was negative, and findings on the electrophysiological study and ablation were similar. We did not systematically study structural associations, including ventricular-valvular interactions, PM morphology or deformation, myocardial scar imaging, mitral disjunction, repolarization mapping, VE mechanism, signal averaged ECG, temporal variation in ECG changes and VE burden, or changes on ambulatory ECG monitoring during menstrual cycles and pregnancy.
Conclusions
BiMVPS is characterized by fascicular and PM VEs that trigger VF, suggesting a central role for the Purkinje system in arrhythmogenesis. Ablation of clinically dominant VE foci improves symptoms and reduces appropriate ICD shocks, but patients require long-term follow-up as new VE foci may arise. However, none of these entities provided any support for this study. The other authors report no conflicts.
